Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Societe Industrielle Limousine D'Application Biologique manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are currently 2 pending office actions for this entity. This suggests a steady level of engagement with the patent office regarding biological applications, indicating a commitment to protecting its research output.
The prosecution involves 2 distinct examiners and 1 distinct art unit. While the company interacts with multiple examiners, all activity is housed within 1 distinct art unit. This structure indicates that while the technical focus is narrow, the company's applications are being reviewed by different individuals within that specific technical group. This can lead to different examination styles even within the same technological field.
CATHERYNE CHEN is the busiest examiner, with 1 busiest examiner pending office action. This represents 1 of the total 2 pending office actions for the portfolio. The other action is managed by the second distinct examiner, showing an even distribution of the current workload across the 2 distinct examiners assigned to the company's filings. This balance prevents any single examiner from having total control over the company's active patent pipeline.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, CATHERYNE | 1 | 37.4% | +18.0% |
| MOREAU, NASHARA LOUISE | 1 | 80.0% | -100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294264 | ACTIVE INGREDIENT COMPRISING OLIGO-GLUCANS DERIVED FROM THE CYTOSOLIC FRACTION OF SACCHAROMYCES CEREVISIAE, AND COSMETIC USES THEREOF | MOREAU, NASHARA LOUISE | 28d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18822670 | Active substance comprising galactomannans from medicago sativa and cosmetic uses thereof | CHEN, CATHERYNE | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18822670 | Active substance comprising galactomannans from medicago sativa and cosmetic uses thereof | CHEN, CATHERYNE | — | §102 | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18294264 | ACTIVE INGREDIENT COMPRISING OLIGO-GLUCANS DERIVED FROM THE CYTOSOLIC FRACTION OF SACCHAROMYCES CEREVISIAE, AND COSMETIC USES THEREOF | MOREAU, NASHARA LOUISE | 1655 | §101§103 | Final Rejection | 28d overdue | Pending | Feb 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial